Endocrinology and Metabolism

Original Articles

Thyroid
Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib: Chae A Kim, Mijin Kim, Meihua Jin, Hee Kyung Kim, Min Ji Jeon, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Dong Yeob Shin, Won Gu Kim; Endocrinol Metab. 2024;39(2):334-343. Published online April 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1854

1,132 View
36 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), serve as valuable prognostic indicators in various cancers. This multicenter, retrospective cohort study assessed the treatment outcomes of lenvatinib in 71 patients with radioactive iodine (RAI)-refractory thyroid cancer, considering the baseline inflammatory biomarkers.
Methods
This study retrospectively included patients from five tertiary hospitals in Korea whose complete blood counts were available before lenvatinib treatment. Progression-free survival (PFS) and overall survival (OS) were evaluated based on the median value of inflammatory biomarkers.
Results
No significant differences in baseline characteristics were observed among patients grouped according to the inflammatory biomarkers, except for older patients with a higher-than-median NLR (≥2) compared to their counterparts with a lower NLR (P= 0.01). Patients with a higher-than-median NLR had significantly shorter PFS (P=0.02) and OS (P=0.017) than those with a lower NLR. In multivariate analysis, a higher-than-median NLR was significantly associated with poor OS (hazard ratio, 3.0; 95% confidence interval, 1.24 to 7.29; P=0.015). However, neither the LMR nor the PLR was associated with PFS. A higher-than-median LMR (≥3.9) was significantly associated with prolonged OS compared to a lower LMR (P=0.036). In contrast, a higher-than-median PLR (≥142.1) was associated with shorter OS compared to a lower PLR (P=0.039).
Conclusion
Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.

Clinical Study
Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment: Oksana Sulaieva, Olena Chernenko, Oleksiy Selesnov, Oleksandr Nechay, Oleksandr Maievskyi, Tetyana Falalyeyeva, Nazarii Kobyliak, Olena Tsyryuk, Yurii Penchuk, Dmytro Shapochka; Endocrinol Metab. 2020;35(2):443-455. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.443

6,680 View
167 Download
12 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The relationship between Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) remains uncertain. We assessed the impact of HT on the tumor immune microenvironment (TIME) in PTC.
Methods
Thirty patients with PTC (group 1) and 30 patients with PTC and HT (group 2) were enrolled in this pilot study. The distribution and number of CD8+ lymphocytes, plasma cells (CD138+), regulatory T cells (forkhead box P3 [FOXP3+)], mast cell tryptase (MCT+), and M2 macrophages (CD163+) were evaluated. To test the hypothesis that HT impacts PTC development via signal transducer and activator of transcription 6 (STAT6) activation and M2 macrophage polarization, we investigated STAT6 expression in tumor and stromal cells. We also evaluated vascular endothelial growth factor (VEGF) expression by lymph node metastasis (LNM) status.
Results
TIME showed significant between-group differences. Group 1 patients demonstrated immune desert or immune-excluded immunophenotypes, while an inflamed phenotype with more CD8+ cells (P<0.001) predominated in group 2. Immune-excluded TIME was associated with the highest LNM rate. In PTC, LNM was associated with more numerous CD163+ cells. Moreover, LNM in group 1 was associated with increased numbers of mast cells peritumorally and FOXP3+ cells intratumorally and peritumorally. Group 2 demonstrated higher STAT6 but not higher VEGF expression in tumor cells. High VEGF expression was associated with LNM regardless of HT status.
Conclusion
Concomitant HT impacted PTC signaling via STAT6 and TIME by increasing the number of CD8+ cells. LNM is associated with increases in CD163+ cells and VEGF expression in PTC, whereas HT affected LNM through different mechanisms.

Citations

Citations to this article as recorded by

Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
Pathology - Research and Practice.2023; 245: 154431. CrossRef
Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance
Peter P. Issa, Ruhul Munshi, Aaron L. Albuck, Mahmoud Omar, Ruba F. Abu Alhuda, Tyler Metz, Mohammad Hussein, Mohamed Shama, Grace S. Lee, Eman Toraih, Emad Kandil
American Journal of Otolaryngology.2023; 44(6): 103994. CrossRef
Hashimoto's thyroiditis is negatively associated with lymph node metastasis in PTMC
Hui Huang, Siyuan Xu, Song Ni, Wensheng Liu, Shaoyan Liu
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15525. CrossRef
A nomogram based on the risk factors of cervical lymph node metastasis in papillary thyroid carcinoma coexistent with Hashimoto’s thyroiditis
Huanhuan Miao, Jingwen Zhong, Xuesha Xing, Jiawei Sun, Jiaqi Wu, Chengwei Wu, Yan Yuan, Xianli Zhou, Hongbo Wang
Clinical Hemorheology and Microcirculation.2023; 85(3): 235. CrossRef
The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
Nese E. GULCELIK, Safak AKIN, Kadriye AYDIN, Cisel AYDIN MERICOZ, Yesim G. GULER TEZEL, Aydan USMAN
Minerva Endocrinology.2023;[Epub] CrossRef
Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer
Meiye Li, Jimei Zhang, Zongjing Zhang, Ying Qian, Wei Qu, Zhaoshun Jiang, Baochang Zhao
Frontiers in Endocrinology.2022;[Epub] CrossRef
A Potential Nine-lncRNAs Signature Identification and Nomogram Diagnostic Model Establishment for Papillary Thyroid Cancer
Jin-Ming Yao, Jun-Yu Zhao, Fang-Fang Lv, Xue-Bo Yang, Huan-Jun Wang
Pathology and Oncology Research.2022;[Epub] CrossRef
Hyperhomocysteinemia in the pathogenesis of cardiovascular and endocrine diseases: translational messages
Rostyslav KAMINSKY, Andrii YANCHYSHYN, Natalia BELEMETS, Olena KURYK, Inga SAMBORSKA, Iryna DZEVULSKA, Rinaldo PELLICANO
Minerva Biotechnology and Biomolecular Research.2022;[Epub] CrossRef
Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
Oleksandr Stakhovskyi, Nazarii Kobyliak, Oleg Voylenko, Eduard Stakhovskyi, Roman Ponomarchuk, Oksana Sulaieva
Cells.2022; 11(11): 1802. CrossRef
Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
Yuepeng Zhang, Yueli Tian
BMC Endocrine Disorders.2022;[Epub] CrossRef
Research Progress in the Correlation between AID, BRAFV600E and Papillary Thyroid Carcinoma
鑫焦
Advances in Clinical Medicine.2022; 12(12): 11503. CrossRef
STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology
Georgia Karpathiou, Alexandra Papoudou-Bai, Elise Ferrand, Jean Marc Dumollard, Michel Peoc’h
Pathology - Research and Practice.2021; 223: 153477. CrossRef
Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
JAMA Network Open.2021; 4(7): e2118526. CrossRef
LARINGOPHARINGEAL REFLUX IMPACTS IMMUNE MICROENVIRONMENT OF LARYNGEAL CARCINOMA
D.I. Zabolotnyi, V.V. Kizim, D.D. Zabolotna, Y.V. Kizim, O.N. Sulaieva
Fiziolohichnyĭ zhurnal.2020; 66(4): 12. CrossRef

First
Prev
Page of 1
Next
Last

Search